Cancer Chemotherapy of Gastrointestinal Tract

Gastrointestinal Tract Cancer

Gastrointestinal Tract Cancer, edited by Martin Lipkin and Robert Good, is a valuable addition to the medical and surgical literature. Individual chapters are contributed by distinguished scientists and clinicians who, with the editors, are to be congratulated on the clarity of presentation and consistency of literary style of the volume as a whole. Figures, tables, and graphs are illustrative ...

Combination chemotherapy in gastrointestinal cancer.

In a prospective, comparative evaluation of therapy in advanced gastrointestinal carcinoma with 5-fluorouracil, mitomycin C, and 1,3-bis-(2-chlorethyl)-l-nitrosourea used alone, in double combination, and in triple combination, 215 adults with proved gastrointestinal adenocarcinoma were randomly assigned to one of seven possible treatment programs. Dosages and schedules were determined from the...

A feasibility, pharmacokinetic and frequency-escalation trial of intraperitoneal chemotherapy in high risk gastrointestinal tract cancer.

AIMS To assess the feasibility, pharmacokinetics and maximum tolerable frequency (MTF) of intraperitoneal (IP) 5-fluorouracil and leucovorin (FU/LV) added, as a regional boost, to intravenous chemotherapy after resection of gastrointestinal cancer. METHODS Fifty-three patients were recruited following gastrointestinal cancer resection (43 colon; 10 stomach/small bowel) with serosal involvemen...

Cancer of the upper gastrointestinal tract.

MiR-signing gastrointestinal (con-)tract cancer

MicroRNAs (miRs) are evolutionary conserved, small non-coding RNAs with a crucial role in regulating genes expression [1]. As they target simultaneously several genes, one miR can eventually control a variety of cellular functions. Therefore, aberrations in the expression of miRs have detrimental repercussions for disease development and progression, including cancer. In the current issue, the ...